tetano
Editor, Senior Moderator
Intern Med
. 2023 Aug 16.
doi: 10.2169/internalmedicine.1648-23. Online ahead of print. Resolution of Eosinophilic Pneumonia after Coronavirus Disease 2019 without Systemic Corticosteroids
Yumiko Misaki[SUP] 1 [/SUP], Yusuke Hayashi[SUP] 1 [/SUP], Masahiro Shirata[SUP] 1 2 [/SUP], Kazuhiro Terada[SUP] 3 [/SUP], Akihiko Yoshizawa[SUP] 3 [/SUP], Ryo Sakamoto[SUP] 4 [/SUP], Kohei Ikezoe[SUP] 1 [/SUP], Kiminobu Tanizawa[SUP] 1 [/SUP], Tomohiro Handa[SUP] 1 5 [/SUP], Toyohiro Hirai[SUP] 1 [/SUP]
Affiliations
Pulmonary and extrapulmonary complications after coronavirus disease 2019 (COVID-19) have been major public health concerns during the COVID-19 pandemic. Although post-COVID-19 pulmonary manifestations cover a wide spectrum, eosinophilic pneumonia (EP) has rarely been reported. To date, only four cases of EP potentially triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been reported, all of which required systemic corticosteroid therapy. We herein report the first case of post-COVID-19 EP resolution without systemic corticosteroid therapy. We also review the literature regarding EP associated with SARS-CoV-2 infection and vaccination.
Keywords: COVID-19; COVID-19 vaccines; SARS-CoV-2; eosinophilic pneumonia.
. 2023 Aug 16.
doi: 10.2169/internalmedicine.1648-23. Online ahead of print. Resolution of Eosinophilic Pneumonia after Coronavirus Disease 2019 without Systemic Corticosteroids
Yumiko Misaki[SUP] 1 [/SUP], Yusuke Hayashi[SUP] 1 [/SUP], Masahiro Shirata[SUP] 1 2 [/SUP], Kazuhiro Terada[SUP] 3 [/SUP], Akihiko Yoshizawa[SUP] 3 [/SUP], Ryo Sakamoto[SUP] 4 [/SUP], Kohei Ikezoe[SUP] 1 [/SUP], Kiminobu Tanizawa[SUP] 1 [/SUP], Tomohiro Handa[SUP] 1 5 [/SUP], Toyohiro Hirai[SUP] 1 [/SUP]
Affiliations
- PMID: 37587039
- DOI: 10.2169/internalmedicine.1648-23
Pulmonary and extrapulmonary complications after coronavirus disease 2019 (COVID-19) have been major public health concerns during the COVID-19 pandemic. Although post-COVID-19 pulmonary manifestations cover a wide spectrum, eosinophilic pneumonia (EP) has rarely been reported. To date, only four cases of EP potentially triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been reported, all of which required systemic corticosteroid therapy. We herein report the first case of post-COVID-19 EP resolution without systemic corticosteroid therapy. We also review the literature regarding EP associated with SARS-CoV-2 infection and vaccination.
Keywords: COVID-19; COVID-19 vaccines; SARS-CoV-2; eosinophilic pneumonia.